FSNUFPNKHealthcare

Fresenius SE & Co. KGaA

Reports in 7d· 2026-05-06

-2.8% · 90d

$54.35

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for FSNUF will appear here as they are published.

Check back later for updates

Key Data

Market Cap$30.61B

Open$57.00

Prev Close$54.35

Day Range$57.00 – $57.00

52W Range$37.73 – $58.16

Volume165

P/E (TTM)17.09

EPS$3.18

Dividend Yield2.27%

Beta0.94

Profit Margin5.53%

Revenue Growth5.20%

Next Earnings2026-05-06(7d)

About

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Healthcare · Medical Care Facilities

131,789 employees

www.fresenius.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

Pacer Advisors, Inc.$119,382

2,074 sh-0.7%

See all holders →